Syndax Pharmaceuticals, Inc.
NASDAQ:SNDXBiotechnology
+$0.13 today
- Market cap
- $770.64M
- Beta
- 0.39
- P/E (TTM)
- -6.8
- EPS (TTM)
- -$2.81
Volume 3.46M
Average 1.70M
SNDX Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Syndax Pharmaceuticals, Inc.NASDAQ: SNDX
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity falls 80.6% from a year ago
Total equity stood at $41.62M at the end of Q1 FY2026, down 80.6% from a year earlier and down 35.6% from the prior quarter. Over 3 fiscal years it compounded at -48.3% a year.
Context
- Total equity amounted to 8.8% of total assets at the end of Q1 FY2026, down 24.8 pp from a year earlier.
- Total equity increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps falling in the next quarterly balance sheet after a -80.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 64.63M USD
- Year-over-year change
- -77.6%
- 4-year CAGR
- -36.9%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 64.63M | -77.6% |
| FY2024 | 2024-12-31 | 288.12M | -48.0% |
| FY2023 | 2023-12-31 | 554.2M | +18.6% |
| FY2022 | 2022-12-31 | 467.45M | +14.5% |
| FY2021 | 2021-12-31 | 408.37M | — |
Total Equity vs competitors
How SNDX compares with its peers on the latest reported figures
- SNDX's Mar 2026 total equity of $41.62M is the 10th highest of the 11 companies compared; the peer median is $289.1M.
- Its year-over-year change of -80.6% is the lowest of 11, against a peer median of -17.2%.
- Total equity amounts to 8.8% of total assets for SNDX, versus a peer median of 66.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Aug 2026 | $968.31M | +160.1% | +21.1% | 81.0% | |
| Jun 2026 | $503.23M | -18.9% | -4.4% | 69.4% | |
| Jun 2026 | $464M | -15.5% | -1.3% | 50.2% | |
| Mar 2026 | $415.56M | +89.1% | +20.0% | 95.1% | |
| Mar 2026 | $319.94M | +1177.3% | — | 89.0% | |
| Sep 2026 | $258.25M | -19.3% | -18.3% | 22.0% | |
| Jun 2026 | $253.86M | -31.9% | -22.4% | 34.1% | |
| Dec 2025 | $210.54M | -56.4% | +0.4% | 63.1% | |
| Mar 2026 | $151.35M | +71.4% | -53.8% | 84.9% | |
| Mar 2026 | $41.62M | -80.6% | -48.3% | 8.8% | |
| Mar 2026 | $21.2M | -73.2% | -26.8% | 9.7% | |
| Peer median (excluding SNDX) | $289.1M | -17.2% | -4.4% | 66.3% | |
Competitors are the stored peer set for SNDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 221.97M | 74.36M | 295.39M | 154.08M | 134.93M |
| Short-term Investments | 224.87M | 410.04M | 282.19M | 428.83M | 278.76M |
| Net Receivables | 429K | 4.06M | 1.23M | 13.87M | 70.29M |
| Inventory | 0 | 0 | 0 | 366K | 32.75M |
| Other Current Assets | 265K | 117K | 63K | (2.02M) | 1.22M |
| Total Current Assets | 448.4M | 489.79M | 580.88M | 603.06M | 528.08M |
| Property, Plant & Equipment (Net) | 1.26M | 1.06M | 1.5M | 2.02M | 1.52M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 5.47M | 29.83M | 119.52M | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 922K | 680K | 217K | 102K |
| Total Non-current Assets | 1.26M | 7.45M | 32M | 121.76M | 1.63M |
| Total Assets | 449.66M | 497.24M | 612.88M | 724.82M | 529.71M |
| Account Payables | 5.67M | 4.35M | 9.96M | 11.63M | 16.58M |
| Short-term Debt | 0 | 0 | 0 | 12.12M | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 6.23M | 6.55M | 35.92M | 15.75M | 103.06M |
| Total Current Liabilities | 20.68M | 29.07M | 58.1M | 103.55M | 120.12M |
| Long-term Debt | 19.9M | 0 | 0 | 331.57M | 344.96M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | (1.05M) |
| Total Non-current Liabilities | 20.61M | 722K | 588K | 333.14M | 344.96M |
| Total Liabilities | 41.29M | 29.79M | 58.68M | 436.69M | 465.08M |
| Common Stock | 6K | 7K | 8K | 9K | 9K |
| Retained Earnings | (543.7M) | (693.04M) | (902.4M) | (1.22B) | (1.51B) |
| Accumulated OCI | 45K | (806K) | 218K | 163K | 452K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 408.37M | 467.45M | 554.2M | 288.12M | 64.63M |
| Total Debt | 20.97M | 1.16M | 1.64M | 345.74M | 346.48M |
| Net Debt | (201M) | (73.2M) | (293.76M) | 191.66M | 211.55M |
Syndax Pharmaceuticals, Inc.
NASDAQ:SNDX
Intrinsic Alpha fair value
Locked
Current Price
$8.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.